Takaaki Tokito

9PUBLICATIONS
23CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsImmunogenetics (incl. genetic immunology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Mar 31, 2026
A Case of Immunotherapy Response to BRAFV600E-Mutant Lung Adenocarcinoma With Initial Resistance to Dabrafenib and Trametinib Combination Therapy.

Yusuke Okayama, Takaaki Tokito, Shizuka Shiraishi

|Sep 05, 2024
Characterization of pre- and on-treatment soluble immune mediators and the tumor microenvironment in NSCLC patients receiving PD-1/L1 inhibitor monotherapy.

Daiki Murata, Koichi Azuma, Kenta Murotani

|Jul 25, 2024
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab as first-line treatment for metastatic non-small cell lung cancer with high levels of programmed death-ligand 1: a randomized, double-blind phase 2 study.

Takaaki Tokito, Oleksii Kolesnik, Jens Sørensen

|May 30, 2024
Treatment patterns and clinical outcomes of resectable clinical stage III non-small cell lung cancer in a Japanese real-world setting: Surgery cohort analysis of the SOLUTION study.

Masahiro Tsuboi, Haruyasu Murakami, Hideyuki Harada

|Nov 15, 2022
Clinical significance of interstitial lung abnormalities and immune checkpoint inhibitor-induced interstitial lung disease in patients with non-small cell lung cancer.

Daiki Murata, Koichi Azuma, Goushi Matama

|Sep 08, 2022
A case of cytokine release syndrome accompanied with COVID-19 infection during treatment with immune checkpoint inhibitors for non-small cell lung cancer.

Daiki Murata, Koichi Azuma, Saeko Tokisawa

Pageof 2

Frequent Collaborators

4 joint publications

Koichi Azuma

3 joint publications

Daiki Murata

1 joint publications

Yuri Taniguchi

1 joint publications

Tsuneo Shimokawa